SMA

Biohaven fails phase 3 SMA test but plans talks with FDA, plots move into obesity
Fierce Biotech
Mon, 11/25/24 - 11:22 am
Biohaven
taldefgrobep alfa
SMA
spinal muscular atrophy
FDA
obesity
Roche files patent suit to fend off potential Evrysdi generics from Zydus, Natco
Fierce Pharma
Wed, 11/20/24 - 11:24 am
Roche
Evrysdi
generics
SMA
patents
Zydus
Natco
Genentech’s Evrysdi helped babies with SMA reach rare milestones in Phase II trial
Clinical Trials Arena
Tue, 10/15/24 - 10:16 am
Roche
SMA
spinal muscular atrophy
Evrysdi
clinical trials
Biogen fills in some of the blanks on its trial of a high-dose version of Spinraza
Fierce Pharma
Wed, 10/9/24 - 09:52 am
Biogen
SMA
spinal muscular atrophy
Spinraza
Scholar Rock scores with ‘surprise’ success in SMA drug study
BioPharma Dive
Mon, 10/7/24 - 11:52 am
Scholar Rock
SMA
spinal muscular atrophy
apitegromab
obesity
Biogen to seek approval for high-dose version of SMA stalwart Spinraza after trial win
Fierce Pharma
Wed, 09/4/24 - 10:49 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
Spinal muscular atrophy market to reach $3bn across 7MM by 2033
Clinical Trials Arena
Wed, 07/17/24 - 09:12 pm
SMA
spinal muscular atrophy
Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children
PM Live
Fri, 06/14/24 - 11:38 am
Roche
SMA
Evrysdi
clinical trials
Roche’s Evrysdi offers sustained benefits in SMA extension trial in children
Clinical Trials Arena
Mon, 06/10/24 - 11:06 am
Roche
clinical trials
Evrysdi
SMA
Biogen, Delta soar together to improve air travel accessibility
Medical Marketing and Media
Thu, 06/6/24 - 09:09 pm
Biogen
philanthropy
SMA
mobility
Novartis reports data from Phase IIIb trial of SMA therapy
Clinical Trials Arena
Tue, 03/5/24 - 11:15 am
Novartis
SMA
clinical trials
Zolgensma
Novartis, Voyager launch another gene therapy mission with $100M upfront deal
Fierce Biotech
Tue, 01/2/24 - 10:05 am
Novartis
gene therapy
Voyager Therapeutics
Huntington's disease
SMA
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
BioSpace
Wed, 10/4/23 - 09:41 am
Roche
Genentech
clinical trials
Evrysdi
SMA
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk
BioSpace
Mon, 07/3/23 - 11:38 am
Genentech
spinal muscular atrophy
SMA
Evrysdi
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
CP Wire
Sun, 03/26/23 - 03:44 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Most-clicked pharma news for week ending March 25: PTC Therapeutics CEO retires and Novartis' Zolgensma shows sustained efficacy
Sun, 03/26/23 - 03:36 pm
PTC Therapeutics
Novartis
Zolgensma
SMA
Novo Nordisk
Ozempic
obesity
diabetes
Baxter
M&A
Celltrio
Thermo Fisher
Pfizer
Astellas
Xtandi
NIH
Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing
NASDAQ
Mon, 03/20/23 - 04:47 pm
Novartis
SMA
Zolgensma
gene therapy
EMA weighs new safety guidance for Novartis’ gene therapy Zolgensma
BioPharma Dive
Tue, 01/17/23 - 10:26 am
Novartis
gene therapy
Zolgensma
SMA
Europe
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Fierce Pharma
Tue, 01/10/23 - 10:55 am
Biogen
Alcyone Therapeutics
SMA
Spinraza
devices
Medtech
Novartis sales of Zolgensma gene therapy slow as market shifts
BioPharma Dive
Tue, 10/25/22 - 11:02 pm
Novartis
gene therapy
spinal muscular atrophy
SMA
Zolgensma

Pages